NCT05909527 2026-03-17
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Guangzhou Bio-gene Technology Co., Ltd
Phase 1/2 Withdrawn
Guangzhou Bio-gene Technology Co., Ltd
Relmada Therapeutics, Inc.
Timser SAPI de CV
Cofactor Genomics, Inc.
Ossium Health, Inc.
Intima Bioscience, Inc.
AstraZeneca
Merck Sharp & Dohme LLC